Antibody Responses After Primary Immunization in Infants Born to Women Receiving a Pertussis-containing Vaccine During Pregnancy: Single Arm Observational Study With a Historical Comparator

Ladhani, Shamez; Andrews, Nick; Southern, Jo; Jones, Christine E; Amirthalingam, Gayatri; Waight, Pauline; England, Anna; Matheson, Mary; Bai, Xilian; Findlow, Helen; Burbidge, Polly; Thalasselis, Vasili; Hallis, Bassam; Green, David; Borrow, Ray; Heath, Paul T; Miller, Elizabeth

doi:10.1093/cid/civ695

Cited by 157 publications

(137 citation statements)

References 17 publications

Supporting

Mentioning

133

Contrasting

Order By: Relevance

“…8 After primary immunization, antibodies to PT (37.2 vs 28.8), FHA (23.0 vs 25.5), and Fim (119 vs 114) were generally comparable between premature and term infants born to vaccinated mothers, but lower than in the sera of the infants of unvaccinated mothers. 1 Given that the UK schedule does not include any further pertussis immunization until children are 3 years old, it is reassuring that the observed differences between the groups had resolved by 12 months of age, a finding also previously reported in term infants. 10 Although post hoc analysis of clinical trial data should be interpreted with caution, these results are biologically plausible and the observed trends are consistent with the recent studies in term infants.…”

Section: Discussionmentioning

confidence: 63%

“…10 Although post hoc analysis of clinical trial data should be interpreted with caution, these results are biologically plausible and the observed trends are consistent with the recent studies in term infants. 1,3,5,10,11 Our findings, therefore, suggest that maternal vaccination early in the third trimester (ie, closer to 28 weeks' gestation, or even earlier, as administered in some settings 12 ) may 3 Due to the design of the vaccination study, fewer infants were sampled at 5 months of age. …”

Section: Discussionmentioning

confidence: 84%

“…1 A combined tetanus, diphtheria, 5-component acellular pertussis, inactivated polio vaccine (Tdap/IPV; Repevax; Sanofi Pasteur, Lyon, France) was offered to all pregnant women from 28 weeks' gestation. The program achieved 64% vaccination coverage in the first year after its introduction, with an estimated 91% effectiveness in preventing confirmed pertussis infections in infants younger than 3 months of age.…”

mentioning

confidence: 99%

See 2 more Smart Citations

Pertussis Antibody Concentrations in Infants Born Prematurely to Mothers Vaccinated in Pregnancy

et al. 2016

Self Cite

View full text Add to dashboard Cite

on behalf of the PUNS study group abstract BACKGROUND AND OBJECTIVES: Maternal antenatal pertussis-containing vaccination is recommended for the prevention of neonatal pertussis, but the ability of maternal vaccination to protect premature infants is unknown. We hypothesized that that infants born prematurely to antenatally vaccinated women would have higher pertussis antibody concentrations than those born to unvaccinated women.

show abstract

Section: Discussionmentioning

confidence: 63%

Section: Discussionmentioning

confidence: 84%

mentioning

confidence: 99%

See 1 more Smart Citation

Pertussis Antibody Concentrations in Infants Born Prematurely to Mothers Vaccinated in Pregnancy

et al. 2016

Self Cite

View full text Add to dashboard Cite

show abstract

“…In the study from England, compared to a historical control group (unvaccinated mothers), immune responses to aP vaccine (including PT, FHA and FIM) were attenuated against all epitopes in those infants born to mothers who received aP vaccine during pregnancy with the geometric mean concentrations being 33–49% lower after the primary series of vaccination. 55 In contrast, although vaccination during pregnancy was associated with high antibody concentrations to PT, pertactin, FHA and FIM at birth, antibody responses to these epitopes did not differ in general between infants born to mothers vaccinated during pregnancy compared to a control group whose mothers were vaccinated post-partum in the USA. An exception was for antibodies to FHA where infants from vaccinated mothers had approximately 2-times lower antibody concentration (p<0.01) at 7 months of age, after receipt of 3 doses of pertussis containing vaccine; this difference was however non-significant at 13 months of age, 1 month after the fourth dose of pertussis vaccine.…”

Section: Maternal Pertussis Vaccinationmentioning

confidence: 77%

Experience and challenges on influenza and pertussis vaccination in pregnant women

Madhi

Nunes

2018

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

Young infants contribute to relatively high burden of vaccine-preventable diseases, including infections by influenza virus and Bordetella pertussis. Vaccination of pregnant women can enhance transplacental transfer of protective antibody to the fetus and protect the infant against disease during the first few months of life.Pregnant women are a priority group for seasonal influenza vaccination, due to third-trimester pregnancy being a risk-factor for severe influenza illness. Furthermore, randomized controlled trials confirmed that influenza vaccination during pregnancy confers protection against influenza-confirmed illness in the women, and their infants up to 3 months of age; and is also associated with 20% reduction in all-cause pneumonia among young-infants. Maternal influenza vaccination might also reduce the risk of low-birth weight, preterm births, and stillbirths however, data on this is conflicting.Vaccination of pregnant women with acellular pertussis vaccines reduces pertussis in their young infants by up to 93%. The increase in specific pertussis antibody among the infants born to vaccinated women might, however, interfere with the active pertussis vaccination of the infant following the primary series of vaccines. The clinical implication of this is yet to be ascertained, particularly since immune responses following the booster vaccine are unaffected.Vaccination of pregnant women with inactivated influenza vaccine and acellular pertussis vaccine have been demonstrated to confer protection to their young infants, and warrants consideration for inclusion into public health immunization programs, including in low and middle income countries.

show abstract

“…According to recent data on the utility and safety of maternal immunization to protect neonates and young infants against pertussis, 126 all pregnant women are advised to receive a dose of the dTap vaccine. While dTap can be given at any time during the pregnancy, in order to maximize the maternal antibody response and passive antibody transfer to the neonate, the best time to administer the vaccine is between 27 and 36 weeks of gestation.…”

Section: Vaccination Of Pregnant Womenmentioning

confidence: 99%

Recommended immunization schedules for adults: Clinical practice guidelines by the Escmid Vaccine Study Group (EVASG), European Geriatric Medicine Society (EUGMS) and the World Association for Infectious Diseases and Immunological Disorders (WAidid)

Esposito

Bonanni

Maggi

et al. 2016

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

Rapid population aging has become a major challenge in the industrialized world and progressive aging is a key reason for making improvement in vaccination a cornerstone of public health strategy. An increase in age-related disorders and conditions is likely to be seen in the near future, and these are risk factors for the occurrence of a number of vaccine-preventable diseases. An improvement in infectious diseases prevention specifically aimed at adults and the elderly can therefore also decrease the burden of these chronic conditions by reducing morbidity, disability, hospital admissions, health costs, mortality rates and, perhaps most importantly, by improving the quality of life. Among adults, it is necessary to identify groups at increased risk of vaccine-preventable diseases and highlight the epidemiological impact and benefits of vaccinations using an evidence-based approach. This document provides clinical practice guidance on immunization for adults in order to provide recommendations for decision makers and healthcare workers in Europe. Although immunization is considered one of the most impactful and cost-effective public health measures that can be undertaken, vaccination coverage rates among adults are largely lower than the stated goal of 95% among adults, and stronger efforts are needed to increase coverage in this population. Active surveillance of adult vaccine-preventable diseases, determining the effectiveness of the vaccines approved for marketing in the last 5 y, the efficacy and safety of vaccines in immunocompromised patients, as well as in pregnant women, represent the priorities for future research.

show abstract

Antibody Responses After Primary Immunization in Infants Born to Women Receiving a Pertussis-containing Vaccine During Pregnancy: Single Arm Observational Study With a Historical Comparator

Cited by 157 publications

References 17 publications

Pertussis Antibody Concentrations in Infants Born Prematurely to Mothers Vaccinated in Pregnancy

Pertussis Antibody Concentrations in Infants Born Prematurely to Mothers Vaccinated in Pregnancy

Experience and challenges on influenza and pertussis vaccination in pregnant women

Recommended immunization schedules for adults: Clinical practice guidelines by the Escmid Vaccine Study Group (EVASG), European Geriatric Medicine Society (EUGMS) and the World Association for Infectious Diseases and Immunological Disorders (WAidid)

Contact Info

Product

Resources

About